Fundamentals:
Pipeline Covering An Existing $25 billion Market
Human growth hormone ($3 billion market, entering Phase II) that could potentially be injected twice per month instead of daily injections. Interferon beta for multiple sclerosis ($4.5 billion market) that may have dramatically lower side effects. Our CTP-enhanced therapeutic proteins pipeline has the potential to dominate a $25 billion market.
CTP -- Nature's Solution To Proteins' Longevity
CTP is a small peptide naturally found in the body as a portion of the hormone hCG, and in fact provides hCG with its superior longevity. We attach CTP to other proteins and significantly increase their lonevity as well.
Merck's FSH-CTP Approved In Europe Jan 2010
Merck and PROLOR have the exclusive license from Washington University to utilize the CTP technology. On January 28, 2010 the European Commission (EC) gave Merck & Co. marketing approval with unified labeling valid in all European Union Member States for FSH-CTP, now branded as ELONVA®
Trend Models
VPHM
Fundamentals:
This is a list of insider-Buys for VPHM for the past year. Note that the last time the "Baker Brothers" (10% owner) bought shares was a year ago and at $6 a share. One year later and at $13 a share, they are buying again. Note also the size of the I-Buy, almost 2,000,000 shares, way more then a year ago at half the share price. Significant?
Trend Models
An interesting feature shared by both of these picks is that both company's are making presentations at Biotechnology conferences this week, VPHM on Tuesday and PBTH on Wednesday. Two stocks with their own stories to tell and possibly catapult respective share prices. Its the game we choose to play.
A
